We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Accelerate Diagnostics (AXDX - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Accelerate Diagnostics is one of 1144 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Accelerate Diagnostics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AXDX's full-year earnings has moved 11.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AXDX has returned about 6% since the start of the calendar year. At the same time, Medical stocks have lost an average of 1.3%. This means that Accelerate Diagnostics is outperforming the sector as a whole this year.
Another stock in the Medical sector, Cognition Therapeutics, Inc. (CGTX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 2.9%.
In Cognition Therapeutics, Inc.'s case, the consensus EPS estimate for the current year increased 38.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Accelerate Diagnostics belongs to the Medical - Instruments industry, a group that includes 94 individual stocks and currently sits at #166 in the Zacks Industry Rank. This group has gained an average of 4.5% so far this year, so AXDX is performing better in this area.
On the other hand, Cognition Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry. This 552-stock industry is currently ranked #106. The industry has moved -5.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Accelerate Diagnostics and Cognition Therapeutics, Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Accelerate Diagnostics (AXDX - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Accelerate Diagnostics is one of 1144 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Accelerate Diagnostics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AXDX's full-year earnings has moved 11.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AXDX has returned about 6% since the start of the calendar year. At the same time, Medical stocks have lost an average of 1.3%. This means that Accelerate Diagnostics is outperforming the sector as a whole this year.
Another stock in the Medical sector, Cognition Therapeutics, Inc. (CGTX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 2.9%.
In Cognition Therapeutics, Inc.'s case, the consensus EPS estimate for the current year increased 38.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Accelerate Diagnostics belongs to the Medical - Instruments industry, a group that includes 94 individual stocks and currently sits at #166 in the Zacks Industry Rank. This group has gained an average of 4.5% so far this year, so AXDX is performing better in this area.
On the other hand, Cognition Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry. This 552-stock industry is currently ranked #106. The industry has moved -5.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Accelerate Diagnostics and Cognition Therapeutics, Inc. as they could maintain their solid performance.